Edition:
United States

Cellect Biotechnology Ltd (APOP.OQ)

APOP.OQ on NASDAQ Stock Exchange Capital Market

2.81USD
14 Dec 2018
Change (% chg)

$-0.30 (-9.65%)
Prev Close
$3.11
Open
$3.05
Day's High
$3.08
Day's Low
$2.81
Volume
3,343
Avg. Vol
3,336
52-wk High
$13.50
52-wk Low
$2.81

Latest Key Developments (Source: Significant Developments)

Cellect Biotechnology reports third quarter results
Tuesday, 13 Nov 2018 07:00am EST 

Nov 13 (Reuters) - Cellect Biotechnology Ltd ::CELLECT BIOTECHNOLOGY PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.CELLECT BIOTECHNOLOGY LTD QTRLY LOSS PER SHARE $0.014.CELLECT BIOTECHNOLOGY - CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $6.45 MILLION AS OF SEPT 30 VERSUS $8.26 MILLION ON JUNE 30.  Full Article

Cellect Biotechnology Q1 Loss Per Ads $0.16
Thursday, 17 May 2018 04:59pm EDT 

May 17 (Reuters) - Cellect Biotechnology Ltd ::CELLECT BIOTECHNOLOGY LTD PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.CELLECT BIOTECHNOLOGY LTD - QTRLY BASIC AND DILUTED LOSS PER ADS $0.16.CELLECT BIOTECHNOLOGY LTD - CASH AND CASH EQUIVALENTS, MARKETABLE SECURITIES AND SHORT-TERM DEPOSITS TOTALED $9.8 MILLION AS OF MARCH 31, 2018.  Full Article

Cellect Announces Opening Of Second Clinical Trial Site And Approval From Safety Board (DSMB) For Dose Escalation
Tuesday, 16 Jan 2018 07:00am EST 

Jan 16 (Reuters) - Cellect Biotechnology Ltd ::CELLECT ANNOUNCES OPENING OF A SECOND CLINICAL TRIAL SITE AND APPROVAL FROM SAFETY BOARD (DSMB) FOR DOSE ESCALATION.CELLECT BIOTECHNOLOGY - ‍SIGNED AGREEMENT WITH HADASSAH MEDICAL CENTER TO CONDUCT CLINICAL TRIALS ON CANCER PATIENTS IN CO'S ONGOING PHASE I/II STUDY​.CELLECT BIOTECHNOLOGY -‍ GOT APPROVAL FROM DSMB TO ESCALATE APOGRAFT FASL PROTEIN DOSAGE TO 25 NG/ML, ENROLL 3 ADDITIONAL PATIENTS FOR CLINICAL TRIAL​.  Full Article

Cellect Biotechnology reports Q3 ‍loss $0.02/shr​
Wednesday, 22 Nov 2017 07:00am EST 

Nov 22 (Reuters) - Cellect Biotechnology Ltd :Cellect Biotechnology Ltd provides corporate update and reports third quarter 2017 financial results.Cellect Biotechnology Ltd - qtrly ‍loss per share $0.02​.  Full Article

No consensus analysis data available.